Your search returned 5 results.

Results
	1.	TKIs beyond immunotherapy predict improved survival in advanced HCC. MedStar authors: Roy, Tina PMID: 35773429 Year: 2023 Citation: Journal of Cancer Research & Clinical Oncology. 149(6):2559-2574, 2023 Jun. Institution: MedStar Georgetown University Hospital/MedStar Washington Hospital Center Department: Internal Medicine Residency Medline publication type: Journal Article Form of publication: Journal Article All authors: Armstrong S, Geng X, Hartley ML, He AR, Jha RC, Kulasekaran M, Prins P, Roy T, Shaukat F, Singh B, Wang H DOI: https://dx.doi.org/10.1007/s00432-022-04115-w Add to cart (remove)
	2.	Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy. [Review] MedStar authors: Barac, Ana Jain, Varun Kenigsberg, Benjamin PMID: 28279416 Year: 2017 Citation: Heart Failure Clinics. 13(2):297-309, 2017 Apr Institution: MedStar Heart & Vascular Institute MedStar Washington Hospital Center Department: Medicine/Cardiology Medline publication type: Journal Article Review Form of publication: Journal Article All authors: Barac A, Jain V, Kenigsberg B DOI: https://dx.doi.org/10.1016/j.hfc.2016.12.002 Add to cart (remove)
	3.	Vemurafenib-induced DRESS. MedStar authors: Jang, Sekwon Nasabzadeh, Teresa Pichard, Dominique C Wenk, Kurt S PMID: 23986488 Year: 2013 Citation: JAMA Dermatology. 149(10):1242-3, 2013 Oct. Institution: MedStar Washington Hospital Center Washington Cancer Institute Department: Dermatology Medline publication type: Case Reports Journal Article Form of publication: Journal Article All authors: Jang S, Nasabzadeh T, Pichard DC, Venna SS, Wenk KS DOI: http://dx.doi.org/10.1001/jamadermatol.2013.5278 Add to cart (remove)
	4.	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. [Review] MedStar authors: Barac, Ana PMID: 34110908 Year: 2021 Citation: Circulation Research. 128(12):1973-1987, 2021 06 11. Institution: MedStar Heart & Vascular Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Barac A, Beckman JA, Fleming MR, Jackson KD, Moslehi JJ, Xiao L DOI: https://dx.doi.org/10.1161/CIRCRESAHA.121.318259 Add to cart (remove)
	5.	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors: Swain, Sandra M PMID: 24095300 Year: 2013 Citation: Lancet Oncology. 14(12):1183-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N DOI: http://dx.doi.org/10.1016/S1470-2045(13)70411-X Add to cart (remove)

Powered by Koha